Compare · EVMN vs NVO
EVMN vs NVO
Side-by-side comparison of Evommune Inc. (EVMN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, EVMN is up 29.6% and NVO is down 34.2% - EVMN leads by 63.8 points.
- EVMN has been more active in the news (13 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 9 for EVMN).
- Company
- Evommune Inc.
- Novo Nordisk A/S
- Price
- $25.62-0.74%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- +10.53%
- +13.32%
- 1Y return
- +29.59%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 13
- 5
- Recent ratings
- 9
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EVMN
- SEC Form 424B3 filed by Evommune Inc.
- SEC Form DEFA14A filed by Evommune Inc.
- SEC Form DEF 14A filed by Evommune Inc.
- SEC Form 4 filed by Patel Jeegar Pravinkumar
- SEC Form 4 filed by Drew Janice Suzann
- SEC Form 4 filed by Bauer Eugene
- SEC Form 4 filed by Carver Kyle
- SEC Form 4 filed by Moss Gregory S.
- SEC Form 4 filed by Pena Luis C.
- SEC Form S-1 filed by Evommune Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S